{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:19:13Z","timestamp":1790291953115,"version":"4.1.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) tracers have reshaped prostate cancer (PC) imaging, supplementing non-PSMA options such as choline-based agents. However, direct comparative performance data across tracers remain scarce, leaving the optimal choice uncertain. We therefore conducted a systematic review and network meta-analysis (NMA) to assess detection rates (DRs) among PET tracers used for primary and biochemically recurrent PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Following PRISMA-NMA guidelines, we systematically searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov through March 2025 for studies comparing 2 PET tracers for prostate cancer. The primary outcome was DR, defined as the proportion of PET-positive patients or lesions. Two reviewers independently extracted data on study design, patient demographics, and imaging parameters, and evaluated quality with QUADAS-2. We performed frequentist random-effects NMA to calculate relative risks (RRs) with 95% CIs, using\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 as reference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Nineteen studies (1681 patients) addressed biochemical recurrence, and 6 (271 patients) targeted primary PC, with 2 overlapping. Risk of bias was low for most domains, though some uncertainty remained for reference standards and timing. In biochemically recurrent PC, PSMA-directed tracers achieved higher DRs than non-PSMA probes. Within the PSMA tracers,\n                      <jats:sup>64<\/jats:sup>\n                      Cu-PSMA-617 achieved the highest estimated DR, followed by\n                      <jats:sup>18<\/jats:sup>\n                      F-DCFPyL,\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007, and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11. Both\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 and\n                      <jats:sup>18<\/jats:sup>\n                      F-DCFPyL showed higher DRs than\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 in primary and recurrent PC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      PSMA tracers outperform non-PSMA alternatives for detecting biochemical recurrence. Among PSMA tracers,\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled agents consistently surpass\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 in both biochemically recurrent and primary PC. When available,\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled PSMA tracers should be preferred.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006349","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:00:39Z","timestamp":1775577639000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Yu-Erh","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Jen-Ai Hospital, Taichung"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kai","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Chung-Kang Branch, Cheng-Ching General Hospital, Taichung"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-6985","authenticated-orcid":false,"given":"Ya-Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Primo Biotechnology Co., Ltd, Taipei"},{"name":"Department of Medical Education and Research, Camillian Saint Mary\u2019s Hospital Luodong, Yilan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-9347","authenticated-orcid":false,"given":"Jing-Ren","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City"},{"name":"School of Medicine, Chang Gung University, Taoyuan, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"(68)Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J Nucl Med"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10585-020-10043-1","article-title":"The clinical efficacy of PSMA PET\/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial","volume":"37","author":"Joshi","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","article-title":"Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten","year":"2020","journal-title":"J Nucl Med"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"101531","DOI":"10.1016\/j.cegh.2024.101531","article-title":"Network meta-analysis: the way forward for evidence-based decisions","volume":"26","author":"Jaiswal","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1016\/j.acra.2025.01.011","article-title":"Diagnostic performance of PET\/CT using different radiotracers in clinically significant primary prostate cancer: a systematic review and network meta-analysis","volume":"32","author":"Chen","year":"2025","journal-title":"Acad Radiol"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"n265","DOI":"10.1136\/bmj.n265","article-title":"Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration","volume":"372","author":"Cohen","year":"2021","journal-title":"Bmj"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/EDE.0000000000000482","article-title":"Sensitivity to excluding treatments in network meta-analysis","volume":"27","author":"Lin","year":"2016","journal-title":"Epidemiology"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jrsm.1455","article-title":"Outlier detection and influence diagnostics in network meta-analysis","volume":"11","author":"Noma","year":"2020","journal-title":"Res Synth Methods"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1097\/RLU.0000000000002794","article-title":"Head-to-head comparison of 18F-prostate-specific membrane antigen-1007 and 18F-fluorocholine PET\/CT in biochemically relapsed prostate cancer","volume":"44","author":"Witkowska-Patena","year":"2019","journal-title":"Clin Nucl Med"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","article-title":"Comparison of 18F-PSMA-1007 and 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study","volume":"44","author":"Panagiotidis","year":"2023","journal-title":"Nucl Med Commun"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00259-023-06301-5","article-title":"[(18)F]DCFPyL PET\/CT versus [(18)F]fluoromethylcholine PET\/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study","volume":"50","author":"Oprea-Lager","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2967\/jnumed.116.185538","article-title":"PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate cancer","volume":"58","author":"Dietlein","year":"2017","journal-title":"J Nucl Med"},{"key":"R28-20260504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clgc.2018.05.014","article-title":"Comparison between (64)Cu-PSMA-617 PET\/CT and (18)F-choline PET\/CT imaging in early diagnosis of prostate cancer biochemical recurrence","volume":"16","author":"Cantiello","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.122.264743","article-title":"Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study","volume":"64","author":"Olivier","year":"2023","journal-title":"J Nucl Med"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s11307-019-01421-7","article-title":"[(68)Ga]Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [(68)Ga]Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence","volume":"22","author":"Green","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"R31-20260504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2967\/jnumed.117.203257","article-title":"Comparison of (68)Ga-PSMA-11 and (18)F-fluciclovine PET\/CT in a case series of 10 patients with prostate cancer recurrence","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"R32-20260504","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/RLU.0000000000002703","article-title":"A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT","volume":"44","author":"Pernthaler","year":"2019","journal-title":"Clin Nucl Med"},{"key":"R33-20260504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R34-20260504","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"R35-20260504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J Nucl Med"},{"key":"R36-20260504","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2967\/jnumed.120.258574","article-title":"Matched-pair comparison of (18)F-DCFPyL PET\/CT and (18)F-PSMA-1007 PET\/CT in 240 prostate cancer patients: interreader agreement and lesion detection rate of suspected lesions","volume":"62","author":"Wondergem","year":"2021","journal-title":"J Nucl Med"},{"key":"R37-20260504","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00259-016-3572-5","article-title":"Detection rate of PET\/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC","volume":"44","author":"Berliner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R38-20260504","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s11307-018-1160-8","article-title":"Imaging characteristics and first experience of [(68)Ga]THP-PSMA, a novel probe for rapid kit-based Ga-68 labeling and PET imaging: comparative analysis with [(68)Ga]PSMA I&T","volume":"20","author":"Derlin","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"R39-20260504","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","article-title":"Head-to-head comparison of [(68) Ga]Ga-P16-093 and [(68) Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R40-20260504","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med"},{"key":"R41-20260504","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","article-title":"Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity","volume":"62","author":"Kroenke","year":"2021","journal-title":"J Nucl Med"},{"key":"R42-20260504","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pros.24294","article-title":"Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer","volume":"82","author":"Vlachostergios","year":"2022","journal-title":"Prostate"},{"key":"R43-20260504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/JU.0000000000001369","article-title":"Detection rate of prostate specific membrane antigen tracers for positron emission tomography\/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis","volume":"205","author":"Crocerossa","year":"2021","journal-title":"J Urol"},{"key":"R44-20260504","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-0045(20000501)43:2<150::AID-PROS10>3.0.CO;2-B","article-title":"A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine","volume":"43","author":"Sokoloff","year":"2000","journal-title":"Prostate"},{"key":"R45-20260504","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"R46-20260504","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"R47-20260504","first-page":"4055","article-title":"Constitutive and antibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res"},{"key":"R48-20260504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cpet.2016.11.002","article-title":"Imaging of prostate cancer using (11)C-choline PET\/computed tomography","volume":"12","author":"Castellucci","year":"2017","journal-title":"PET Clin"},{"key":"R49-20260504","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00259-017-3700-x","article-title":"PET and PET\/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies","volume":"44","author":"Giovacchini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R50-20260504","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1097\/RLU.0b013e31829af913","article-title":"The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng\/mL","volume":"38","author":"Mamede","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R51-20260504","doi-asserted-by":"crossref","first-page":"844","DOI":"10.21037\/tau.2018.08.26","article-title":"Clinical implications of PET\/CT in prostate cancer management","volume":"7","author":"Rayn","year":"2018","journal-title":"Transl Androl Urol"},{"key":"R52-20260504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/nu10010023","article-title":"Characterisation of L-type amino acid transporter 1 (LAT1) expression in human skeletal muscle by immunofluorescent microscopy","volume":"10","author":"Hodson","year":"2017","journal-title":"Nutrients"},{"key":"R53-20260504","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00259-013-2403-1","article-title":"The clinical safety, biodistribution and internal radiation dosimetry of [\u00b9\u2078F]fluciclovine in healthy adult volunteers","volume":"40","author":"McParland","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R54-20260504","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R55-20260504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00259-012-2291-9","article-title":"Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer","volume":"40","author":"S\u00f6rensen","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R56-20260504","first-page":"277","article-title":"(64)Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first in-human studies","volume":"31","author":"Grubm\u00fcller","year":"2016","journal-title":"Cancer Biother Radiopharm"},{"key":"R57-20260504","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","article-title":"Physics of pure and non-pure positron emitters for PET: a review and a discussion","volume":"3","author":"Conti","year":"2016","journal-title":"EJNMMI Phys"},{"key":"R58-20260504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2967\/jnumed.117.190157","article-title":"(68)Ga or (18)F for prostate cancer imaging?","volume":"58","author":"Kesch","year":"2017","journal-title":"J Nucl Med"},{"key":"R59-20260504","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00259-018-3952-0","article-title":"Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R60-20260504","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2967\/jnumed.120.257741","article-title":"Combination of forced diuresis with additional late imaging in (68)Ga-PSMA-11 PET\/CT: effects on lesion visibility and radiotracer uptake","volume":"62","author":"Alberts","year":"2021","journal-title":"J Nucl Med"},{"key":"R61-20260504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"R62-20260504","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","article-title":"First-in-human imaging with 89Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake","volume":"57","author":"Pandit-Taskar","year":"2016","journal-title":"J Nucl Med"},{"key":"R63-20260504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","article-title":"Meta-analysis of (18) F-PSMA-1007 PET\/CT, (18) F-FDG PET\/CT, and (68)Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer","volume":"23","author":"Yu","year":"2023","journal-title":"Cancer Imaging"},{"key":"R64-20260504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jclinepi.2017.11.018","article-title":"Node-making process in network meta-analysis of nonpharmacological treatment are poorly reported","volume":"97","author":"James","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"R65-20260504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J Nucl Med"},{"key":"R66-20260504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12874-023-01896-7","article-title":"Connecting a disconnected trial network with a new trial: optimizing the estimation of a comparative effect in a network meta-analysis","volume":"23","author":"McKeen","year":"2023","journal-title":"BMC Med Res Methodol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:01:11Z","timestamp":1777921271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006349"}},"subtitle":["A Systematic Review and Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006349","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2025-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}